DB09: T-DXd + Pertuzumab Challenges the Cleopatra Regimen in First-Line Metastatic Disease

DESTINY-Breast09 delivers an unprecedented median Progression-Free Survival (PFS) of over 40 months. Drs. Pegram and Iyengar detail how the T-DXd + Pertuzumab combination nearly doubles the PFS achieved by the long-standing CLEOPATRA regimen.